File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of chronic lymphocytic leukaemia

TitleManagement of chronic lymphocytic leukaemia
Authors
KeywordsCombined Modality Therapy
Leukemia
Lymph Nodes
Lymphoid
Rituximab
Issue Date2011
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org
Citation
Hong Kong Journal Of Radiology, 2011, v. 14 n. 4 SUPPL., p. 56-62 How to Cite?
AbstractChronic lymphocytic leukaemia is a disease that primarily affects the elderly and has a heterogeneous clinical course. The past decade has witnessed extensive progress in its management, owing to the generation of prognostic biological markers that influence therapeutic decisions, as well as the development of novel therapeutic agents that improve the treatment response and survival. This review discusses the value of various prognostic markers in the management of chronic lymphocytic leukaemia and the treatment options with conventional chemotherapy and newer chemoimmunotherapy regimens. However, treatment needs to be tailored to individual patients according to the patient's general physical state, ability to tolerate treatment-related toxicity, and presence of comorbidities. To that end, an approach to formulating primary and secondary treatment decisions is also presented. © 2011 Hong Kong College of Radiologists.
Persistent Identifierhttp://hdl.handle.net/10722/163484
ISSN
2015 SCImago Journal Rankings: 0.113
References

 

DC FieldValueLanguage
dc.contributor.authorTse, Een_US
dc.contributor.authorSingh Gill, Hen_US
dc.date.accessioned2012-09-05T05:31:52Z-
dc.date.available2012-09-05T05:31:52Z-
dc.date.issued2011en_US
dc.identifier.citationHong Kong Journal Of Radiology, 2011, v. 14 n. 4 SUPPL., p. 56-62en_US
dc.identifier.issn2223-6619en_US
dc.identifier.urihttp://hdl.handle.net/10722/163484-
dc.description.abstractChronic lymphocytic leukaemia is a disease that primarily affects the elderly and has a heterogeneous clinical course. The past decade has witnessed extensive progress in its management, owing to the generation of prognostic biological markers that influence therapeutic decisions, as well as the development of novel therapeutic agents that improve the treatment response and survival. This review discusses the value of various prognostic markers in the management of chronic lymphocytic leukaemia and the treatment options with conventional chemotherapy and newer chemoimmunotherapy regimens. However, treatment needs to be tailored to individual patients according to the patient's general physical state, ability to tolerate treatment-related toxicity, and presence of comorbidities. To that end, an approach to formulating primary and secondary treatment decisions is also presented. © 2011 Hong Kong College of Radiologists.en_US
dc.languageengen_US
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.orgen_US
dc.relation.ispartofHong Kong Journal of Radiologyen_US
dc.subjectCombined Modality Therapyen_US
dc.subjectLeukemiaen_US
dc.subjectLymph Nodesen_US
dc.subjectLymphoiden_US
dc.subjectRituximaben_US
dc.titleManagement of chronic lymphocytic leukaemiaen_US
dc.typeArticleen_US
dc.identifier.emailTse, E:ewctse@hku.hken_US
dc.identifier.authorityTse, E=rp00471en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-84860299771en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84860299771&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume14en_US
dc.identifier.issue4 SUPPL.en_US
dc.identifier.spage56en_US
dc.identifier.epage62en_US
dc.publisher.placeHong Kongen_US
dc.identifier.scopusauthoridTse, E=7005019454en_US
dc.identifier.scopusauthoridSingh Gill, H=55199478200en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats